Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
|Articles|October 10, 2017
Colorscience introduces Clinical Redness Corrector
All Calm™ Clinical Redness Corrector is formulated for redness, rosacea and sensitive skin, according to the company.
Advertisement
All Calm™ Clinical Redness Corrector is formulated for redness, rosacea and sensitive skin, according to the company. It calms and soothes skin while neutralizing redness. A patent-pending complex helps provide ongoing relief from sensitivity and the appearance of redness. In addition, it includes full-spectrum UVA/UVB SPF 50 sun protection via 100% mineral, chemical-free active ingredients.
FOR MORE INFORMATION:
Advertisement
Related to this article
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
5